Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease Source: Eur Respir J 2009; 33: 148-152 Year: 2009
Long-term survival of patients with mycobacterium avium- intracellulare complex pulmonary disease (MAC-PD) Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008
The clinical effect of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease - including a long-term follow-up study Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005
The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study Source: Eur Respir J, 56 (3) 1901875; 10.1183/13993003.01875-2019 Year: 2020
Hair-analysis for acetyl-isoniazid/isoniazid ratio and N-acetyl-transferase-2-genotype in patients on treatment for mycobacterium tuberculosis infection Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011
Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009
Risk factors for Mycobacterium tuberculosis infection among contacts of pulmonary tuberculosis patients Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012
Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systemic review and meta-analysis Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
Isolation of M. abscessus from patients with M. avium complex (MAC) lung disease Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013
Impact of T-SPOT.TB test to exclude active Mycobacterium tuberculosis complex infection in patients with mycobacterial disease Source: Eur Respir J 2006; 28: Suppl. 50, 139s Year: 2006
Mycobacterium abscessus respiratory infection: importance in immunosuppressed patientsSource: Annual Congress 2008 - Lung and bone marrow transplantation: miscellaneous Year: 2008
Evaluating the use of the interferon-γ response to mycobacterium tuberculosis (MTB) specific antigens to diagnose latent tuberculosis infection in patients with chronic inflammatory joint and skin diseases Source: Annual Congress 2011 - Tuberculin skin tests, interferon-gamma release assays and beyond Year: 2011
M ycobacterium abscessus pulmonary disease: individual patient data meta-analysisSource: Eur Respir J, 54 (1) 1801991; 10.1183/13993003.01991-2018 Year: 2019
Pulmonary tuberculosis Source: Respipedia Article Year: 2018